More information: Tomohiko Ishihara et al, L-arginine in patients with spinocerebellar ataxia type 6: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, eClinicalMedicine ...

A recent study of clinical and genetic characteristics in patients with hereditary spastic ... core clinical symptoms (pyramidal signs versus ataxia), might offer a more pertinent way to approach ...

Currently under review in the U.S. for a rare genetic disorder, the drug is seen by some investors as critical to Biohaven’s ...

Steminent Biotherapeutics specializes in developing innovative stem cell-based therapeutics that offer new hope for patients ...

Biohaven Ltd. on Monday announced that New York-based Oberland Capital has agreed to invest up to $600 million in the New ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the ...

Biohaven has secured a funding deal worth up to $600m from Oberland Capital Management, providing the biotech with ...

Biohaven will use the money to bankroll commercial preparations for the spinocerebellar ataxia drug candidate troriluzole, ...